Trials of Diabetes Drug Aleglitazar Scrapped

American College of Cardiology

| May 10, 2014

After a phase III study that showed no reduction in cardiovascular events for those with diabetes, continued trials for the diabetes drug Aleglitazar have been scrapped.
The results were revealed at the 2014 American College of Cardiology Scientific Sessions.

Previous studies had showed reductions in A1c, triglycerides and LDL, or "bad" cholesterol, while raising levels of good cholesterol.

The current phase, however, while revealing a reduction in A1c levels as well as cholesterol, failed to have an impact on cardiovascular events, leading the Swiss drug maker, Roche, to terminate this and all further studies of the drug.

In addition to showing no cardiovascular benefits, the drug - a peroxisome proliferator-activated receptor agonist - has been associated with an increased risk of hypoglycemia, bone fractures, renal abnormalities and cardiovascular.

Drugs in this class have also been linked to an increased risk of cancer.

Click Here To View Or Post Comments

Categories: A1c , American College of Cardiology, Cardiovascular, Diabetes


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • What's on the Horizon with Diabetes Research and Therapy
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated

Latest American College of Cardiology Articles

Print | Email | Share | Comments (0)

You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.